Doğanay Güler, Ekmekçi Perihan, Kazbek Baturay Kansu, Yılmaz Hakan, Erkan Gülbanu, Tüzüner Filiz
Department of Anesthesiology and Reanimation, Ufuk University Dr. Rıdvan Ege Hospital, Ankara, Turkey.
Turk J Gastroenterol. 2017 Nov;28(6):453-459. doi: 10.5152/tjg.2017.16489. Epub 2017 Sep 19.
BACKGROUND/AIMS: To assess the effect of propofol supplemented with alfentanil or fentanyl on cognitive functions for sedation during elective colonoscopy.
Patients (n=150, 18-65 years old, American Society of Anesthesiologists risk group I-III) scheduled undergo elective colonoscopy were included. They were randomized into three groups using the closed envelope methodpropofol-alfentanil (Group A), propofol-fentanyl (Group F), and propofol only (Group P).Group A patients were given an alfentanil (10 mcg/kg)-supplemented propofol bolus infusion and 5 mcg/kg alfentanil when necessary. Group F patients were given fentanyl (1 mcg/kg)-supplemented propofol and 0.5 mcg/kg fentanyl when necessary. Group P patients were given 1 mg/kg propofol and 0.5 mg/kg propofol when necessary. Vital signs, depth of sedation, recovery parameters, and patient and endoscopist satisfaction were recorded. Trieger dot test (TDT) and Digit Symbol Substitution Test (DSST) were performed post procedure.
Demographic data were similar among all patients in the groups. Bispectral index values were lower in Group P (p<0.001). DSST scores were higher in Group A (p=0.004). TDT scores and Facial Pain Scale scores were higher in Group P (p<0.005). Apnea incidence (p=0.009) and Observer's Assessment of Alertness/Sedation Scale scores (p=0.002) were also higher in Group P. Patient satisfaction and endoscopist satisfaction were similar among all patients.
Compared with propofol-alfentanil and propofol-fentanyl, propofol alone is associated with an increased incidence of apnea, drug consumption, and reported pain. Propofol-alfentanil has a less negative effect on cognitive functions than propofol alone or propofol-fentanyl.
背景/目的:评估丙泊酚联合阿芬太尼或芬太尼用于择期结肠镜检查镇静时对认知功能的影响。
纳入计划接受择期结肠镜检查的患者(n = 150,年龄18 - 65岁,美国麻醉医师协会风险分级I - III级)。采用封闭信封法将他们随机分为三组:丙泊酚 - 阿芬太尼组(A组)、丙泊酚 - 芬太尼组(F组)和单纯丙泊酚组(P组)。A组患者给予补充阿芬太尼(10 mcg/kg)的丙泊酚推注输注,必要时给予5 mcg/kg阿芬太尼。F组患者给予补充芬太尼(1 mcg/kg)的丙泊酚,必要时给予0.5 mcg/kg芬太尼。P组患者给予1 mg/kg丙泊酚,必要时给予0.5 mg/kg丙泊酚。记录生命体征、镇静深度、恢复参数以及患者和内镜医师的满意度。术后进行特里格点试验(TDT)和数字符号替换试验(DSST)。
三组患者的人口统计学数据相似。P组的脑电双频指数值较低(p < 0.001)。A组的DSST评分较高(p = 0.004)。P组的TDT评分和面部疼痛量表评分较高(p < 0.005)。P组的呼吸暂停发生率(p = 0.009)和观察者警觉/镇静量表评分(p = 0.002)也较高。所有患者的患者满意度和内镜医师满意度相似。
与丙泊酚 - 阿芬太尼和丙泊酚 - 芬太尼相比,单纯丙泊酚与呼吸暂停发生率增加、药物消耗量增加及疼痛报告增多相关。丙泊酚 - 阿芬太尼对认知功能的负面影响小于单纯丙泊酚或丙泊酚 - 芬太尼。